Sugi Predict

Sugi Predict / Compounds / SCHEMBL1907784

SCHEMBL1907784

SCHEMBL1907784

CC(C)(C)OC(=O)N1CCN(c2ccc(Cl)cc2F)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.56
▸ CYP3A5 P20815 2/20 0.56
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ GRM5 P41594 1/20 0.52
▸ USP30 Q70CQ3 1/20 0.52
▸ MAPT P10636 7/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ STS P08842 1/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ PHGDH O43175 1/20 0.47
▸ LMNA P02545 3/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30591201 1.00 CYP3A4 (0.56) CYP3A4CYP3A5MEN1KMT2AGRM5
SCHEMBL31342680 0.95 MEN1 (0.59) CYP3A4CYP3A5MEN1KMT2AGRM5
SCHEMBL20657938 0.91 MEN1 (0.55) CYP3A4CYP3A5MEN1KMT2AUSP30
SCHEMBL30208133 0.88 MEN1 (0.58) CYP3A4CYP3A5MEN1KMT2AGRM5
SCHEMBL2365793 0.88 MEN1 (0.58) CYP3A4CYP3A5MEN1KMT2AGRM5
SCHEMBL22532774 0.86 SMN1; SMN2 (0.56) MEN1KMT2AGRM5MAPTL3MBTL1
SCHEMBL23535945 0.86 USP30 (0.49) CYP3A4CYP3A5MEN1KMT2AGRM5
SCHEMBL29931954 0.86 USP30 (0.49) CYP3A4CYP3A5MEN1KMT2AGRM5
SCHEMBL25326735 0.86 USP30 (0.47) CYP3A4CYP3A5MEN1KMT2AGRM5
SCHEMBL3929365 0.85 L3MBTL1 (0.55) MEN1KMT2AMAPTL3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109864-A1 SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 2024-04-04 — — US disclosed
CN-116829545-A Substituted pyrazolylpiperidine carboxylic acids 拜耳公司 2023-09-29 — — CN disclosed
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2023-03-16 — — US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed
WO-2022150461-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2022-07-14 — — WO disclosed
WO-2022122916-A1 SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 2022-06-16 — — WO disclosed
EP-3953332-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 Therapeutics, Inc. (US) 2022-02-16 — — EP disclosed
CN-113677664-A Tricyclic degradants of IKAROS and AIOLOS C4医药公司 2021-11-19 — — CN disclosed
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 — — US disclosed
US-7935703-B2 Piperazines and piperidines as Mglur5 potentiators ASTRAZENECA AB (SE) 2011-05-03 — — US disclosed
US-7935703-B2 Piperazines and piperidines as Mglur5 potentiators ASTRAZENECA AB (SE) 2011-05-03 — — US disclosed
US-7935703-B2 Piperazines and piperidines as Mglur5 potentiators ASTRAZENECA AB (SE) 2011-05-03 — — US disclosed
EP-1979320-B1 PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS ASTRAZENECA AB (SE) 2009-10-21 — — EP disclosed
US-20090023711-A1 Piperazines and Piperidines as Mglur5 Potentiators ASTRAZENECA AB (SE) 2009-01-22 — — US disclosed
US-20090023711-A1 Piperazines and Piperidines as Mglur5 Potentiators ASTRAZENECA AB (SE) 2009-01-22 — — US disclosed
US-20090023711-A1 Piperazines and Piperidines as Mglur5 Potentiators ASTRAZENECA AB (SE) 2009-01-22 — — US disclosed
EP-1979320-A2 PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS AstraZeneca AB (SE) 2008-10-15 — — EP disclosed
WO-2007087135-A2 PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS ASTRAZENECA AB (SE) 2007-08-02 — — WO disclosed
WO-2007087135-A2 PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS ASTRAZENECA AB (SE) 2007-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023711-A1 Piperazines and Piperidines as Mglur5 Potentiators GRM5, GRM1, GRIN1 CYP3A4 3938/4885CYP3A5 1136/4885MEN1 3974/4885
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 CYP3A4 1961/4885CYP3A5 3189/4885MEN1 2242/4885
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS CRBN, IKZF1, IKZF3 CYP3A4 1961/4885CYP3A5 3189/4885MEN1 2242/4885
US-20240109864-A1 SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS PLOD3, PDK4, PDF CYP3A4 4071/4885CYP3A5 3774/4885MEN1 4399/4885
US-10851084-B2 Piperazine derivatives as TRPML modulators TRPM5, TRPM2, TRPM4 CYP3A4 4628/4885CYP3A5 4389/4885MEN1 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.